{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T07:17:12Z","timestamp":1793949432749,"version":"4.8.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.diabres.2026.113158","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T15:58:28Z","timestamp":1771516708000},"page":"113158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Glucagon-like peptide-1 receptor agonists and the risk of obesity-related cancers: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"234","author":[{"given":"Yousef A.","family":"Ateiwi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahil","family":"Mahmood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hon Jen","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen Ee","family":"Low","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun En","family":"Yau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainsley Ryan Yan Bin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei Chia","family":"Eng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilda","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark Y.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Hui","family":"Sia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2026.113158_b0005","article-title":"Global, regional, and national burden of type 2 diabetes mellitus caused by high BMI from 1990 to 2021, and forecasts to 2045: analysis from the global burden of disease study 2021","volume":"13","author":"Huang","year":"2025","journal-title":"Front Public Health"},{"issue":"5","key":"10.1016\/j.diabres.2026.113158_b0010","article-title":"Recent trends in GLP-1 RA and SGLT2i use among people with type 2 diabetes and atherosclerotic cardiovascular disease in the USA","volume":"12","author":"Aaron","year":"2024","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"1","key":"10.1016\/j.diabres.2026.113158_b0015","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"10.1016\/j.diabres.2026.113158_b0020","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2337\/dc24-1678","article-title":"Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: a systematic review, meta-analysis, and meta-regression of 47 randomized controlled trials","volume":"48","author":"Wong","year":"2025","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.diabres.2026.113158_b0025","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/HJH.0000000000003903","article-title":"Effects of glucagon-like peptide-1 receptor agonists on blood pressure in overweight or obese patients: a meta-analysis of randomized controlled trials","volume":"43","author":"Wong","year":"2025","journal-title":"J Hypertens"},{"key":"10.1016\/j.diabres.2026.113158_b0030","article-title":"Type 2 diabetes, obesity, and cancer share some common and critical pathways","volume":"10\u20132020","author":"Rahman","year":"2021","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.diabres.2026.113158_b0035","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.3390\/antiox13091109","article-title":"Oxidative stress and age-related tumors","volume":"13","author":"Di Carlo","year":"2024","journal-title":"Antioxidants"},{"issue":"4","key":"10.1016\/j.diabres.2026.113158_b0040","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s10555-024-10192-9","article-title":"The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer","volume":"43","author":"Ibrahim","year":"2024","journal-title":"Cancer Metastasis Rev"},{"issue":"6","key":"10.1016\/j.diabres.2026.113158_b0045","first-page":"C1822","article-title":"GLP-1 receptor agonists in the context of cancer: the road ahead","volume":"328","author":"Miousse","year":"2025","journal-title":"Am J Phys Cell Phys"},{"issue":"7","key":"10.1016\/j.diabres.2026.113158_b0050","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.21305","article-title":"Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.diabres.2026.113158_b0055","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2337\/dc22-1148","article-title":"GLP-1 receptor agonists and the risk of thyroid cancer","volume":"46","author":"Bezin","year":"2022","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.diabres.2026.113158_b0060","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40364-025-00765-3","article-title":"Glucagon-like peptide 1 receptor agonists and cancer risk: advancing precision medicine through mechanistic understanding and clinical evidence","volume":"13","author":"Lin","year":"2025","journal-title":"Biomarker Res"},{"issue":"8","key":"10.1016\/j.diabres.2026.113158_b0065","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1111\/dom.16489","article-title":"GLP-1 receptor agonists and the risk for cancer: a meta-analysis of randomized controlled trials","volume":"27","author":"Silverii","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2026.113158_b0070","article-title":"statement: an updated guideline for reporting systematic reviews","volume":"2021","author":"Page","year":"2020","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.diabres.2026.113158_b0075","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1056\/NEJMsr1606602","article-title":"Body fatness and cancer \u2014 viewpoint of the IARC working group","volume":"375","author":"Lauby-Secretan","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.diabres.2026.113158_b0080","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrc1408","article-title":"Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms","volume":"4","author":"Calle","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"10.1016\/j.diabres.2026.113158_b0085","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nrc3967","article-title":"Adiposity and cancer risk: new mechanistic insights from epidemiology","volume":"15","author":"Renehan","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.diabres.2026.113158_b0090","unstructured":"World Health Organization. Regional Office for the Western P. The Asia-Pacific perspective : redefining obesity and its treatment: Sydney : Health Communications Australia; 2000 2000."},{"key":"10.1016\/j.diabres.2026.113158_b0095","series-title":"JBI Manual for Evidence Synthesis","article-title":"Chapter 7: Systematic reviews of etiology and risk","author":"Moola","year":"2020"},{"key":"10.1016\/j.diabres.2026.113158_b0100","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.diabres.2026.113158_b0105","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jclinepi.2010.09.011","article-title":"GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.diabres.2026.113158_b0110","unstructured":"Higgins JPT TJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions: Cochrane; 2024. Available from: https:\/\/www.cochrane.org\/handbook."},{"key":"10.1016\/j.diabres.2026.113158_b0115","unstructured":"Organization WH. Countries: World Health Organization; 2025 [Available from: https:\/\/www.who.int\/countries."},{"key":"10.1016\/j.diabres.2026.113158_b0120","doi-asserted-by":"crossref","unstructured":"Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10(10):Ed000142.","DOI":"10.1002\/14651858.ED000142"},{"issue":"11","key":"10.1016\/j.diabres.2026.113158_b0125","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.diabres.2026.113158_b0130","article-title":"Association between incretin-based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: a large population-based matched cohort study","volume":"38","author":"Krishnan","year":"2024","journal-title":"J Clin Transl Endocrinol"},{"key":"10.1016\/j.diabres.2026.113158_b0135","doi-asserted-by":"crossref","unstructured":"Funch D, Mortimer K, Ziyadeh NJ, J DS, Zhou L, Ng E, et al. Risk of Thyroid Cancer Associated with Use of Liraglutide and Other Antidiabetic Drugs in a US Commercially Insured Population. Diabetes Metab Syndr Obes. 2021;14:2619-29.","DOI":"10.2147\/DMSO.S305496"},{"key":"10.1016\/j.diabres.2026.113158_b0140","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2147\/DMSO.S171503","article-title":"Is there an association between liraglutide use and female breast cancer in a real-world setting?","volume":"11","author":"Funch","year":"2018","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"11","key":"10.1016\/j.diabres.2026.113158_b0145","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1001\/jamainternmed.2024.4661","article-title":"GLP-1 receptor agonists and risk for cirrhosis and related complications in patients with metabolic dysfunction-associated steatotic liver disease","volume":"184","author":"Kanwal","year":"2024","journal-title":"JAMA Intern Med"},{"issue":"1","key":"10.1016\/j.diabres.2026.113158_b0150","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.50408","article-title":"Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk in patients with type 2 diabetes","volume":"7","author":"Dankner","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.diabres.2026.113158_b0155","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078225","article-title":"Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: scandinavian cohort study","volume":"385","author":"Pasternak","year":"2024","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.diabres.2026.113158_b0160","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1097\/HEP.0000000000000712","article-title":"Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: a scandinavian cohort study","volume":"79","author":"Engstr\u00f6m","year":"2024","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.diabres.2026.113158_b0165","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4093\/dmj.2024.0105","article-title":"Use of glucagon-like peptide-1 receptor agonists does not increase the risk of cancer in patients with type 2 diabetes mellitus","volume":"49","author":"Kim","year":"2025","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.diabres.2026.113158_b0170","article-title":"Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study","volume":"363","author":"Abrahami","year":"2018","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.diabres.2026.113158_b0175","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/EDE.0000000000000793","article-title":"Incretin-based drugs and the incidence of colorectal cancer in patients with type 2 diabetes","volume":"29","author":"Abrahami","year":"2018","journal-title":"Epidemiology"},{"issue":"10","key":"10.1016\/j.diabres.2026.113158_b0180","doi-asserted-by":"crossref","DOI":"10.1111\/1753-0407.70013","article-title":"The potential adverse effects of hypodermic glucagon-like peptide -1 receptor agoniston patients with type 2 diabetes: a population-based study","volume":"16","author":"Cheng","year":"2024","journal-title":"J Diabetes"},{"issue":"10","key":"10.1016\/j.diabres.2026.113158_b0185","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1007\/s00125-021-05508-1","article-title":"Use of incretin-based drugs and risk of cholangiocarcinoma: scandinavian cohort study","volume":"64","author":"Ueda","year":"2021","journal-title":"Diabetologia"},{"issue":"8","key":"10.1016\/j.diabres.2026.113158_b0190","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2337\/dc17-1825","article-title":"Neoplasms reported with liraglutide or placebo in people with type 2 diabetes: results from the LEADER randomized trial","volume":"41","author":"Nauck","year":"2018","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.diabres.2026.113158_b0195","doi-asserted-by":"crossref","first-page":"444","DOI":"10.2337\/dc24-1903","article-title":"Glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors and the prevention of cirrhosis among patients with type 2 diabetes","volume":"48","author":"Pradhan","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2026.113158_b0200","article-title":"Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2 diabetes: population based cohort study using the UK clinical practice research datalink","volume":"355","author":"Hicks","year":"2016","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.diabres.2026.113158_b0205","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1111\/dom.13739","article-title":"Liraglutide use and evaluation of pancreatic outcomes in a US commercially insured population","volume":"21","author":"Funch","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.diabres.2026.113158_b0210","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12916-023-03228-4","article-title":"Effects of glucagon-like peptide-1 receptor agonists on liver-related and cardiovascular mortality in patients with type 2 diabetes","volume":"22","author":"Yen","year":"2024","journal-title":"BMC Med"},{"issue":"9","key":"10.1016\/j.diabres.2026.113158_b0215","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1111\/apt.17925","article-title":"Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes","volume":"59","author":"Elsaid","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.diabres.2026.113158_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2025.101346","article-title":"Long-term cancer risk in users of GLP-1 agonists in Denmark: a nationwide emulated trial","volume":"55","author":"Gamborg","year":"2025","journal-title":"The Lancet Regional Health \u2013 Europe"},{"issue":"10","key":"10.1016\/j.diabres.2026.113158_b0225","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1001\/jamaoncol.2025.2681","article-title":"GLP-1 receptor agonists and cancer risk in adults with obesity","volume":"11","author":"Dai","year":"2025","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.diabres.2026.113158_b0230","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1093\/jnci\/djaf163","article-title":"Association between glucagon-like peptidase 1 receptor agonist and obesity-related cancer in overweight or obese patients with type 2 diabetes: a nationwide cohort study","volume":"117","author":"Mao","year":"2025","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.diabres.2026.113158_b0235","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s40264-025-01551-8","article-title":"Incretin-based drugs and the incidence of endometrial cancer among people with type 2 diabetes: active comparator new-user design","volume":"48","author":"Rothman","year":"2025","journal-title":"Drug Saf"},{"key":"10.1016\/j.diabres.2026.113158_b0240","unstructured":"Lu Y, Dai H, Tang H, Donahoo WT, George TJ, Sun RC, et al. Association of Glucagon-Like Peptide-1 Receptor Agonists With Cancer Risk in Older Adults With Type 2 Diabetes. Obesity.n\/a(n\/a)."},{"key":"10.1016\/j.diabres.2026.113158_b0245","unstructured":"Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists. Annals of Internal Medicine.0(0):null."},{"issue":"5","key":"10.1016\/j.diabres.2026.113158_b0250","doi-asserted-by":"crossref","first-page":"330","DOI":"10.4093\/dmj.2014.38.5.330","article-title":"Hyperglycemia as a risk factor for cancer progression","volume":"38","author":"Ryu","year":"2014","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.diabres.2026.113158_b0255","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2021.668368","article-title":"SGLT-2i and risk of malignancy in type 2 diabetes: a meta-analysis of randomized controlled trials","volume":"9","author":"Shi","year":"2021","journal-title":"Front Public Health"},{"issue":"Supplement_2","key":"10.1016\/j.diabres.2026.113158_b0260","doi-asserted-by":"crossref","first-page":"S240","DOI":"10.2337\/dcS13-2002","article-title":"Insulin therapy and cancer","volume":"36","author":"Home","year":"2013","journal-title":"Diabetes Care"},{"issue":"Supplement_1","key":"10.1016\/j.diabres.2026.113158_b0265","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehae666.2917","article-title":"Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis","volume":"45","author":"Lobo","year":"2024","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.diabres.2026.113158_b0270","doi-asserted-by":"crossref","DOI":"10.1186\/s12902-024-01775-2","article-title":"Risk of hepatocellular carcinoma with glucagon-like Peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis","volume":"24","author":"Shabil","year":"2024","journal-title":"BMC Endocr Disord"},{"issue":"2","key":"10.1016\/j.diabres.2026.113158_b0275","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.3390\/ijms24021703","article-title":"GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives","volume":"24","author":"Nevola","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.diabres.2026.113158_b0280","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1210\/en.2009-1272","article-title":"Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation","volume":"151","author":"Bjerre Knudsen","year":"2010","journal-title":"Endocrinology"},{"issue":"4","key":"10.1016\/j.diabres.2026.113158_b0285","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3803\/EnM.2014.29.4.536","article-title":"Expression of glucagon-like Peptide-1 receptor in papillary thyroid carcinoma and its clinicopathologic significance","volume":"29","author":"Jung","year":"2014","journal-title":"Endocrinol Metab (Seoul)"},{"key":"10.1016\/j.diabres.2026.113158_b0290","doi-asserted-by":"crossref","first-page":"5621","DOI":"10.2147\/OTT.S150701","article-title":"Effects of insulin analogs and glucagon-like peptide-1 receptor agonists on proliferation and cellular energy metabolism in papillary thyroid cancer","volume":"10","author":"He","year":"2017","journal-title":"OncoTargets and Therapy"},{"issue":"3","key":"10.1016\/j.diabres.2026.113158_b0295","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/dom.15382","article-title":"Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"26","author":"Silverii","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2026.113158_b0300","article-title":"Effects of GLP-1 receptor agonists on biological behavior of colorectal cancer cells by regulating PI3K\/AKT\/mTOR signaling pathway","volume":"13\u20132022","author":"Tong","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.diabres.2026.113158_b0305","doi-asserted-by":"crossref","unstructured":"Zhao H-j, Jiang X, Hu L-j, Yang L, Deng L-d, Wang Y-p, et al. Activation of GLP-1 receptor enhances the chemosensitivity of pancreatic cancer cells. Journal of Molecular Endocrinology. 2020;64(2):103-13.","DOI":"10.1530\/JME-19-0186"},{"issue":"9","key":"10.1016\/j.diabres.2026.113158_b0310","first-page":"1319","article-title":"Cardiovascular, diabetes, and cancer strips: evidences, mechanisms, and classifications","volume":"6","author":"Hu","year":"2014","journal-title":"J Thorac Dis"},{"issue":"1","key":"10.1016\/j.diabres.2026.113158_b0315","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s13659-024-00432-4","article-title":"Marine natural products and human immunity: novel biomedical resources for anti-infection of SARS-CoV-2 and related cardiovascular disease","volume":"14","author":"Hu","year":"2024","journal-title":"Nat Prod Bioprospect"},{"key":"10.1016\/j.diabres.2026.113158_b0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2025.102727","article-title":"Prevention of cardiovascular disease for healthy aging and longevity: a new scoring system and related \u201cmechanisms-hallmarks-biomarkers\u201d","volume":"107","author":"Hu","year":"2025","journal-title":"Ageing Res Rev"},{"issue":"1","key":"10.1016\/j.diabres.2026.113158_b0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2024.167563","article-title":"Linking COVID-19 and cancer: underlying mechanism","volume":"1871","author":"Tyagi","year":"2025","journal-title":"Biochim Biophys Acta (BBA) - Mol Basis Dis"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882272600077X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882272600077X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T01:46:56Z","timestamp":1780105616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016882272600077X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":65,"alternative-id":["S016882272600077X"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113158","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucagon-like peptide-1 receptor agonists and the risk of obesity-related cancers: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113158","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113158"}}